| P2093 | author name string | M A Johnson | |
| | K H Moore | |
| | A Bye | |
| | G E Pakes | |
| | G J Yuen | |
| P2860 | cites work | Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Delta Coordinating Committee | Q71264278 |
| | Interaction between lamivudine (3TC) and other nucleoside analogues for intracellular phosphorylation | Q71303575 |
| | Renal disposition and drug interaction screening of (-)-2'-deoxy-3'-thiacytidine (3TC) in the isolated perfused rat kidney | Q71485760 |
| | A preliminary trial of lamivudine for chronic hepatitis B infection | Q71523548 |
| | Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. North American HIV Working Party | Q71523552 |
| | A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team | Q71545355 |
| | Mitochondrial toxicity--new adverse drug effects | Q71758950 |
| | Determination of 2'-deoxy-3'-thiacytidine (3TC) in human urine by liquid chromatography: direct injection with column switching | Q71994759 |
| | High-performance liquid chromatographic assay for 2'-deoxy-3'-thiacytidine in human serum | Q72784034 |
| | Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: the CAESAR trial | Q73368842 |
| | Increased fidelity of drug-selected M184V mutated HIV-1 reverse transcriptase as the basis for the effectiveness of 3TC in HIV clinical trials | Q73480869 |
| | Lamivudine treatment of advanced and decompensated liver disease due to hepatitis B | Q73509549 |
| | Lamivudine therapy for chronic hepatitis B: a six-month randomized dose-ranging study | Q73760619 |
| | The pharmacokinetics of lamivudine in patients with impaired hepatic function | Q77062067 |
| | (-)-2'-deoxy-3'-thiacytidine is a potent, highly selective inhibitor of human immunodeficiency virus type 1 and type 2 replication in vitro | Q28316326 |
| | Effects of (-)-2'-deoxy-3'-thiacytidine (3TC) 5'-triphosphate on human immunodeficiency virus reverse transcriptase and mammalian DNA polymerases alpha, beta, and gamma | Q28316436 |
| | The separated enantiomers of 2'-deoxy-3'-thiacytidine (BCH 189) both inhibit human immunodeficiency virus replication in vitro | Q28319933 |
| | The anti-hepatitis B virus activities, cytotoxicities, and anabolic profiles of the (-) and (+) enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine | Q28327158 |
| | Anti-human immunodeficiency virus type 1 activity and in vitro toxicity of 2'-deoxy-3'-thiacytidine (BCH-189), a novel heterocyclic nucleoside analog | Q28333679 |
| | The safety and pharmacokinetics of a reverse transcriptase inhibitor, 3TC, in patients with HIV infection | Q28342763 |
| | Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase | Q28368030 |
| | Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy | Q34294256 |
| | A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team | Q34438252 |
| | Analysis of mutations at position 184 in reverse transcriptase of human immunodeficiency virus type 1. | Q35116619 |
| | Pharmacokinetics of lamivudine and BCH-189 in plasma and cerebrospinal fluid of nonhuman primates | Q35120992 |
| | Pharmacokinetics of lamivudine in human immunodeficiency virus-infected patients with renal dysfunction. | Q35125144 |
| | Single dose pharmacokinetics of lamivudine in subjects with impaired renal function and the effect of haemodialysis | Q35803067 |
| | Interspecies scaling and pharmacokinetic parameters of 3TC in humans | Q36677354 |
| | Clinical pharmacokinetics of nucleoside antiretroviral agents | Q40596588 |
| | Lamivudine (3TC) phosphorylation and drug interactions in vitro | Q40880707 |
| | Lamivudine in children with human immunodeficiency virus infection: a phase I/II study. The National Cancer Institute Pediatric Branch-Human Immunodeficiency Virus Working Group | Q40936139 |
| | Lamivudine. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in the management of HIV infection | Q41429010 |
| | Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel | Q41513115 |
| | Deoxycytidine deaminase-resistant stereoisomer is the active form of (+/-)-2',3'-dideoxy-3'-thiacytidine in the inhibition of hepatitis B virus replication | Q41614034 |
| | Cellular metabolism of (−) enantiomeric 2′-deoxy-3′-thiacytidine | Q41623558 |
| | The biochemical basis for the differential anti-human immunodeficiency virus activity of two cis enantiomers of 2',3'-dideoxy-3'-thiacytidine | Q42278288 |
| | A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. | Q42541246 |
| | Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: a placebo-controlled trial. | Q42551686 |
| | Pharmacokinetics, absolute bioavailability, and absorption characteristics of lamivudine | Q42635952 |
| | Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation | Q43635554 |
| | Drug resistance and virologic response in NUCA 3001, a randomized trial of lamivudine (3TC) versus zidovudine (ZDV) versus ZDV plus 3TC in previously untreated patients. | Q44034071 |
| | Divergent anti-human immunodeficiency virus activity and anabolic phosphorylation of 2',3'-dideoxynucleoside analogs in resting and activated human cells. | Q44037704 |
| | Safety and efficacy of lamivudine-zidovudine combination therapy in zidovudine-experienced patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group | Q45222610 |
| | Pharmacokinetics and antiretroviral activity of lamivudine alone or when coadministered with zidovudine in human immunodeficiency virus type 1-infected pregnant women and their offspring | Q45753331 |
| | Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group | Q45755649 |
| | Alteration of the dismal natural history of fibrosing cholestatic hepatitis secondary to hepatitis B virus with the use of lamivudine | Q45760202 |
| | Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy | Q45760702 |
| | A phase I/II study of 2'-deoxy-3'-thiacytidine (lamivudine) in patients with advanced human immunodeficiency virus infection | Q45785396 |
| | Evaluation of safety and efficacy of 3TC (lamivudine) in patients with asymptomatic or mildly symptomatic human immunodeficiency virus infection: a phase I/II study | Q45785688 |
| | Combination alpha-interferon and lamivudine therapy for alpha-interferon-resistant chronic hepatitis B infection: results of a pilot study | Q47809579 |
| | Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group. | Q53984825 |
| | Pharmacokinetics of stavudine in patients with AIDS or AIDS-related complex | Q67494226 |
| | Comparison of cytotoxicity of the (-)- and (+)-enantiomer of 2',3'-dideoxy-3'-thiacytidine in normal human bone marrow progenitor cells | Q67507205 |
| | Pharmacokinetics of lamivudine administered alone and with trimethoprim-sulfamethoxazole | Q71117298 |
| | Lamivudine plus zidovudine compared with zalcitabine plus zidovudine in patients with HIV infection. A randomized, double-blind, placebo-controlled trial. North American HIV Working Party | Q71208878 |
| P433 | issue | 1 | |
| P921 | main subject | pharmacokinetics | Q323936 |
| P304 | page(s) | 41-66 | |
| P577 | publication date | 1999-01-01 | |
| P1433 | published in | Clinical Pharmacokinetics | Q5133788 |
| P1476 | title | Clinical pharmacokinetics of lamivudine | |
| P478 | volume | 36 | |